Small cell lung cancer
Clinical research is centered on small cell lung cancer (SCLC), with attention to relapsed disease and treatment options for patients whose cancer has returned after prior therapy.
- Relapsed SCLC
- Lung cancer oncology
- Thoracic malignancies
The sponsor’s activity in this area reflects a focused interest in oncology for aggressive pulmonary cancers, particularly where treatment resistance and disease recurrence remain major clinical concerns.
Immuno-oncology
Research includes the use of immune checkpoint therapy in combination strategies for cancer immunotherapy, with emphasis on treatment approaches that engage the immune system in advanced lung cancer.
- PD-1 inhibition
- Checkpoint blockade
- Combination immunotherapy
This area highlights interest in integrating immunotherapy with other anticancer agents to address difficult-to-treat malignancies.
Anticancer pharmacology
The funded research examines a lurbinectedin-based treatment approach, placing emphasis on antineoplastic agents used in combination regimens for recurrent lung cancer.
- Lurbinectedin
- Antitumor activity
- Combination oncology treatment
Interest in this domain is directed toward therapeutic options for solid tumors with limited standard treatment pathways.
Clinical pharmacokinetics
The sponsor also supports investigation of drug behavior in the body, with attention to pharmacokinetic profiling in patients receiving combined anticancer therapy.
- Pharmacokinetic assessment
- Therapeutic exposure
- Oncology drug combination
This reflects involvement in understanding how systemic cancer treatments interact within complex therapeutic settings.
Multicenter cancer care
Research activity spans multicenter clinical oncology involving collaboration across several research sites in Madrid and within Spain, supporting patient access to specialist cancer treatment research.
- Collaborative oncology networks
- Hospital-based research
- Specialist trial coordination
The sponsor is engaged in a focused clinical environment for advanced lung cancer research within a hospital setting.
